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ICBS and ECBS Chemical Biology Meeting 2015 - Let Them Come to
Berlin!
Toru Komatsu*,†,§ and Satpal Virdee*,‡
†Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
§JST PRESTO, Tokyo, Japan
‡MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, United Kingdom
Chemical biology largely concerns the development ofchemically inspired tools for probing biological processes.
Such tools range from small molecule probes that enable the
selective perturbation of biomolecules involved in cellular
pathways, to methodology that enables the construction of
biomolecules themselves that are otherwise inaccessible.
Researchers working at the chemistry and biology interface
have contributed signiﬁcantly to our understanding of bio-
logical phenomena and how they can be modulated for
therapeutic beneﬁt. The growth of this ﬁeld has driven the
assembly of a global network. The International Chemical
Biology Society (ICBS) was launched with an inaugural
conference held at the University of Kansas (USA, 2011). In
2015, ICBS jointly convened with the European Chemical
Biology Symposium, a series of symposia organized since 2008
by the European EU-OPENSCREEN consortium. This ﬁrst
joint ICBS and ECBS conference was held in Berlin on
October 7−9, 2015. During the meeting, ideas were exchanged
over cutting-edge research that covered emerging topics in
chemical biology, such as chemoproteomics, epigenetics,
conjugates for target delivery, anti-infectives, chemoinformatics
and chemical systems biology, molecular imaging, and post-
translational modiﬁcations (PTMs). The three day meeting was
held at Langenbeck Virchow House. The venue, restored to its
1915 state, was a real treat for the >250 participants from all
over the world. The pleasure extended to a particularly
memorable second evening at the Museum Für Naturkunde
where participants dined in the Dinosaur Hall in awe of the
fantastic exhibits on display.
On the ﬁrst day, the meeting started with a welcome note by
Phil Gribbon (Coordinator of EU-OPENSCREEN at Leibniz-
Institut fu ̈r Molekulare Pharmakologie FMP in Berlin,
Germany) and Mel Reichman (Lankenau Institute for
Medical Research, USA), President of ICBS. The scientiﬁc
session began with a keynote lecture by Timothy J. Mitchison
(Harvard Medical School, USA). His lecture started with the
question, “How do anti-microtubule drugs work in man?”
Taking taxanes, a commonly used class of anti-microtubule
chemotherapy drug as an example, he discussed the diﬀerence
in mode of function for single drugs in cellulo and in vivo.1 For
example, in culture, paclitaxel causes mitotic arrest and
apoptosis of most treated cells, but this is not true in vivo, in
part because of the diﬀerences in S phase cell populations and
doubling time between these two settings. He introduced his
latest studies aimed at ﬁlling this gap. The talk featured
thoughtful insights explaining that even established taxane
drugs have multiple and complex functions in controlling
cellular phenotypes.2−4 This plenary keynote lecture provided a
stimulating opening to the conference.
■ CHEMOPROTEOMICS
The keynote lecture was followed by the ﬁrst session entitled
“Chemoproteomics.” Chemoproteomics connects proteomics
with pharmacology or chemical biology.5,6 In previous decades
pharmacology (modulation of protein function with tool
compounds or drugs) was the major approach to understanding
novel protein functions, but as a result of recent progress in
genome sequencing, genetic studies are being used more
frequently to discover direct connections between mutations
and human disorders. The idea of chemoproteomics is to
leverage the use of pharmacological or chemical-biological tools
to facilitate target discovery. One of the important pillars of
chemoproteomics is forward chemical genetics, or forward drug
discovery. In this approach, compounds that give rise to cellular
phenotypes are discovered, and the target protein is
characterized afterward, so the chance of discovering novel
protein functions is much higher.5,7 However, in such a
phenotypic screening approach, the bottleneck is target
identiﬁcation.8 Many solutions to this long-standing problem
have been developed, but so far there is no gold standard. One
recently developed and promising technology is the cellular
thermal shift assay (CETSA).9 The assay is based on the
biophysical principle of ligand-induced thermal stabilization.
The application of thermal shift assays in a cellular format
allows studies on target engagement of drug candidates in a
cellular context. Thomas Lundbac̈k (Chemical Biology
Consortium Sweden, Sweden) introduced CETSA techniques
with successful research examples.10 Next, Bernhard Ku ̈ster
(Technical University of Munich, Germany) described
chemical proteomic strategies for proﬁling the speciﬁcities of
kinase inhibitors.
Following those talks, Ben Cravatt (The Scripps Research
Institute, USA) spoke on recent discoveries of novel protein
functions, focusing on application of the activity-based protein
proﬁling (ABPP) technique to serine hydrolases.11 Serine
hydrolases are an important class of proteins whose functions
and relations to disease are poorly understood.12,13 He
introduced an elegant study aimed at understanding the
functions of a poorly characterized enzyme named
ABHD12.14 He not only successfully characterized ABHD12
as lysophosphatidylserine lipase but also built on this ﬁnding to
unveil the molecular mechanism of the neurodegenerative
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disease PHARC. He further proceeded to propose ways to treat
the disease by the development of proof-of-concept inhibitors.
This study represents a role model for studies aimed at
connecting benchside to bedside.
Next, Michael Bradshaw (Principia Biopharma, USA)
described the elegant development of a potent inhibitor of the
tyrosine kinase, BTK. The key to achieving high potency was
enhancing residence time at the enzyme active site.15 This was
realized by the use of “warhead chemistry” reported by Jack
Taunton’s lab that targets proximal cysteine residues in a
covalent, but reversible, manner.16 In principle, the described
warhead chemistry can be applied to any inhibitor that binds
proximal to a cysteine residue, rendering the inhibitor more
potent and speciﬁc. It will be very interesting to see how these
inhibitors fare during clinical development.
Technologies for labeling proteins with small ﬂuorescent
probes in living cells are invaluable for determining cellular
localization and realizing the potential of super resolution
microscopy. However, a drawback with classical methods is the
background ﬂuorescence from unreacted probe material. To
address this, a number of probes that demonstrate turn-on
ﬂuorescence have been developed. However, these chemistries
target speciﬁc tags or biorthogonal handles that need to be
artiﬁcially introduced into the protein under study. Probes that
can speciﬁcally target canonical amino acids with turn-on
properties are lacking. For the last talk of the session, Kosuke
Dodo (RIKEN, Japan) described a proximity-reactive O-NBD
(nitrobenzoxadiazole) probe with turn-on ﬂuorescence that
targets the ε-amino functionality of lysine residues.17 The utility
of this technology was demonstrated by attaching the O-NBD
moiety to a N,N-dialkyl-2-phenylindol-3-yloxylamide (PIGA)
ligand that binds translocator protein (TSPO). The probe
selectively labeled mitochondria expressing TSPO, and 2D
PAGE analysis also revealed that a VDAC (voltage-dependent
anion channel) was labeled.
■ EPIGENETICS
In the following session, four researchers discussed “Epige-
netics.” First, Chuan He (The University of Chicago, USA)
introduced RNA methylation, which has been less characterized
than the DNA counterpart.18,19 The importance of RNA
methylation was recognized, following his discovery of enzymes
that reversibly control N6-methyladenosine (m6A) states on
mRNA.20,21 Besides enzymes that control methylation states,
other important regulatory proteins in RNA methylation are
methylation-speciﬁc binding proteins that control translation
status or the lifetime of mRNA.22,23 He introduced his
discovery of these proteins, along with a novel member that
mediates m6A methylation on nuclear RNA.
Next, Angelina Measures (University of Oxford, UK)
talked about the important role of “reader” proteins that
recognize methylation/acetylation of histone lysine residues to
control transcription.24 She discussed the discovery of
inhibitors of a reader domain using the AlphaScreen platform,
supported by computational approaches. The tool compounds
discovered should be useful to test the druggability of these
domains, as well as providing tools to study the “epigenetic
code” by modulating reader protein function.
The potential druggability of epigenetic proteins is still a
matter of discussion,25,26 though some interesting drug
candidates have already been developed by pharmaceutical
companies.27 Under these circumstances, academic researchers
have much work to do in driving forward our understanding of
the intrinsic nature of epigenetic control of biological
phenomena. Some pioneering work was next introduced by
Masatoshi Hagiwara (Kyoto University, Japan), who has been
working on the development of novel ways to treat diseases by
controlling the transcriptome. He compared drug discovery to
the traditional Japanese sport of horseback bow-shooting.
Hitting a target with an arrow ﬁred from a running horse is not
an easy task and requires good timing, suﬃcient skill, and great
concentration, but fortunately there are many targets on the
way, so even if the rider misses one target, another one is never
far away. He described three small-molecule hits from a high-
throughput screen and their optimization. The molecules
controlled exon skipping (causative of genetic diseases such as
Duchenne muscular dystrophy),28 exon inclusion (causative of
genetic diseases such as familial dysautonomia),29 and the
transcription of a broad spectrum of DNA viruses.30 Despite
the diﬃculties in achieving each goal, the results were
promising and clearly illustrate the power of small-molecular
drugs for controlling diseases related to epigenetic events.
Another successful hit compound was reported by Maria Duca
(Institute of Chemistry of Nice, France), who described a
small-molecular inhibitor that targets miRNA production.31
The second Keynote talk followed and was delivered by
David Tirrell (Caltech, USA). A testament to the utility of
chemical biology tools is their ability to garner new biological
insight. The talk described the validation and application of
biorthogonal, noncanonical amino acid tagging (BONCAT) to
a whole range of systems from microorganisms to animals.32,33
BONCAT allows the incorporation of the unnatural amino acid
azidohomoalanine (Aha) by the endogenous protein translation
machinery. Aha pulsed into cultured cells, or animals, results in
the incorporation of Aha into subsequently synthesized
proteins. The biorthogonal azido group displayed by Aha can
then be coupled to a biotin puriﬁcation handle, or a ﬂuorescent
probe. A derivative of BONCAT employed an evolved
synthetase that selectively incorporated the azido-functionalized
amino acid (Anl). The use of speciﬁc promoters to drive
transcription of the mutant synthetase thereby restricts Anl
incorporation to speciﬁc cells and tissue types. These two
approaches form the basis of a powerful platform for studying
newly synthesized proteins in cells, animals, and host−
pathogen systems.34
■ CONJUGATES FOR TARGETED DELIVERY
The second day began with a session entitled “Conjugates for
targeted delivery.” Antibodies are an important class of
therapeutics, with excellent disease-homing properties. While
antibodies alone can have potent biological activity, antibodies
“armed” with additional functionality can be more eﬃcient and
serve as powerful therapeutic tools, representing an attractive
ﬁeld for chemical biologists. As an example, Dario Neri (ETH
Zürich, Switzerland) introduced the art of fusing anti-
inﬂammatory cytokines with disease-homing antibodies to
generate immunocytokines.35 The idea of boosting the activity
of the immune system against tumors has been considered
promising for a long time, but the use of cytokine alone is
insuﬃcient due to the lack of potency and selectivity for target
tumor sites. The idea of immunocytokines is to utilize
antibodies or antibody fragments as pharmacodelivery vehicles
for cytokines. This approach is very eﬀective, as was shown by a
number of examples, including TNFα-conjugated anti-EDB-
ﬁbronectin human antibody L19 and IL-2-conjugated L19,
agents that were conﬁrmed to be eﬀective in patients.36 Besides
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these novel antibody-based therapeutics, he also outlined
another project aiming to develop potent binders based on
DNA-encoded chemical libraries. He has developed small
molecules with ultrahigh binding aﬃnity (sub-nM Kd) for their
targets, rivalling that of antibodies.37 Furthermore, by using
ﬂuorescent conjugates, accumulation in tumor sites of model
mice was clearly observed. Bypassing antibodies enables facile
handling, quality control consistency, optimization, and
derivatization. In short, this is a powerful way to develop
functional therapeutic tools based on chemical-biological
knowledge.
A current limitation of biologics for cytosolic targets is their
ineﬃcient delivery across the plasma membrane. Cell
penetrating peptides (CPPs) oﬀer potential to deliver such
cargoes, and the next two talks focused on developments in this
area. Jean-Phillipe Pellois (Texas A&M University, USA)
described a variant of the TAT peptide that could eﬃciently
deliver a number of cargoes into the cytosol of mammalian
cells.38 The CPP consisted of a disulﬁde-linked TAT dimer
conjugated to a tetramethylrhodamine (TAMRA) ﬂuorophore.
Cell uptake was demonstrated to be mediated by endocytosis
followed by endosome escape. The ineﬃciency of this latter
step has limited the utility of conventional CPPs, so this
approach appears to be a signiﬁcant advance. A somewhat
conﬂicting talk followed from Henry David Herce (Rensselaer
Polytechnic Institute, USA) describing cyclized versions of
TAT that similarly enabled substantially enhanced delivery of
protein cargoes.39 However, it was proposed that endosome
escape is not involved in CPP delivery, but rather direct
diﬀusion through the plasma membrane. Together, these two
strategies should increase the options available for macro-
molecule delivery into cells.
The next speaker was David Margulies (Weizmann
Institute, Israel). His talk described work on rewiring signaling
pathways with chemical transducers. A potential application of
this research is the development of novel modes of therapy.
One interesting aspect involved the use of oligonucleotide
(ODN)−small molecule conjugates that could be used to
couple platelet-derived growth factor (PDGF) to activation of
an enzyme, in this case, glutathione-S-transferase (GST).40 Pro-
drug release could be programmed by Boolean logic such that
GST activity and hence PDGF (where high levels are secreted
by certain cancer cells) are both required. This technology was
demonstrated as a proof of concept experiment in cell-free
medium, so it will be interesting to see how these approaches
can be extended to cells.
To wrap up the session, Hidde Ploegh (Whitehead
Institute, USA) presented some of his latest work. Here,
modiﬁed single domain antibody fragments (VHHs) were used
as tools to detect immune cells and thereby use their inﬁltration
of cancer cells to indirectly and noninvasively image tumors.41
The small size of VHHs enabled their functionalization with a
number of modiﬁcations such as PET tracers and ﬂuorophores,
using versatile sortase-mediated reactions.42 The VHH format
also enables cytosolic expression in mammalian cells, allowing
measurement of phenotypic eﬀects arising from perturbation of
speciﬁc protein−protein interactions.
■ RISING STARS IN CHEMICAL BIOLOGY
A traditional component of ICBS meetings is a Rising Stars
session, where up and coming young chemical biologists are
given well-deserved recognition. This year’s winners were
Alessio Ciulli (University of Dundee, UK), Evan Miller
(Berkley, USA), and Edward Lemke (EMBL, Germany).
Alessio presented his work on establishing “bump and hole”
approaches to Bromo and Extra-Terminal (BET) proteins.43,44
Originally pioneered by the Shokat lab, the “bump and hole”
approach is a chemical genetic method that can be used to
obtain enzyme family member selectivity based on an otherwise
pan-speciﬁc small molecule inhibitor.45 BET proteins contain
bromodomains that are dedicated recognition modules of
lysine-acetylation marks on histone tails. Pan-speciﬁc inhibitors
of BET family proteins have been developed (e.g., I-BET) that
appear as a promising mode of therapy against several cancers
and are currently in clinical trials.46 While there has been keen
interest in developing BET family member-speciﬁc inhibitors, it
is not clear which family member to target. Alessio’s approach
involved mutating a conserved leucine residue in the
bromodomain binding pocket to alanine.43 This “hole” was
then complemented by the introduction of an ethyl “bump” on
the I-BET scaﬀold. The selectivity imparted by this approach
toward a speciﬁc bromodomain in a BET family member was
∼2 orders of magnitude. The approach should prove valuable
for probing the individual roles of bromodomains within
speciﬁc BET family members. The next part of Alessio’s talk
described the development of novel proteolysis-targeted
chimeras (PROTACs).47 PROTACs are bifunctional com-
pounds containing components that bind a target protein and a
promiscuous E3 ligase. This permits reassignment of the E3
ligase to that of the target protein. The ubiquitination of the
target protein results in its degradation by the proteasome. A
key aspect of this strategy is that the protein is not simply
inhibited, but removed from the cell in a substoichiometric
manner (i.e., a single PROTAC can initiate the degradation of
multiple copies of the target protein). Alessio’s example utilized
the VHL E3 ligase that was redirected to the previously
discussed BET proteins.48 Similar approaches have been
reported by other laboratories highlighting the potential general
applicability of this novel mode of therapy.47
The next recipient was Evan Miller (Berkley, USA), who
talked about the development of small molecule voltage sensors
that can be used as probes of neuronal activity.49,50 Membrane
potential (Vmem) is classically measured with electrodes using
patch clamp methods, which limits measurements to a single
cell. Optical techniques are far less invasive and are amenable to
higher throughput execution. However, existing optical
approaches only provide an indirect measure of Vmem. Evan
described powerful probes such as BeRST that provide a direct
measure of Vmem.
50 Variants that were photoactivatable, thereby
conferring spatial resolution, were also described.49 These
probes should be valuable for the noninvasive and multicellular
study of neuronal activity.
Edward Lemke (EMBL, Germany) spoke on bioorthogonal
labeling of proteins in cells with ﬂuorescent probes, with
particular focus on methodologies that enable multicolor
labeling.51,52 His methods were based on the genetic
incorporation of unnatural amino acids (UAAs) bearing
strained ene and yne functionality. By tuning the kinetics of
the popular strain promoted inverse-electron-demand Diels−
Alder cycloaddition (SPIEDAC) reaction, a new and
orthogonal variant was developed termed selectivity enhanced
SPIEDAC (seSPIEDAC).51 In conjunction with a bispeciﬁc
UAA incorporation system, the utility of this approach was
demonstrated by the labeling of two populations of the insulin
receptor with two distinct probes.
ACS Chemical Biology In Focus
DOI: 10.1021/acschembio.6b00268
ACS Chem. Biol. 2016, 11, 1159−1166
1161
The session was rounded oﬀ with a Keynote Talk by Carolyn
Bertozzi (Stanford University, USA). Carolyn discussed the
application of the revolutionary bioorthogonal chemistries her
lab has developed to peptidodoglycan imaging.53,54 This
involved metabolic incorporation of unnatural D-amino acids,
bearing click handles, into peptidoglycans and subsequent
labeling with ﬂuorescent dyes using bioorthogonal chemistry
such as copper-catalyzed azide−alkyne cycloaddition
(CuAAC). Her studies provided signiﬁcant insight into
peptidoglycan dynamics of Listeria in the context of infected
macrophages. As an example, by monitoring the labeling of the
bacterial pole and the septum upon macrophage infection, it
was apparent that bacterial division was halted, and elongation
becomes more pronounced.
■ ANTI-INFECTIVES
The Nobel Prize in Physiology or Medicine 2015 was awarded
to three researchers who developed novel therapeutics for
infectious diseases based on complex natural products.
Discovery of natural products with signiﬁcant biological activity
has been one of the hottest areas in chemical biology, and in
the session “Anti-infectives,” excellent talks on constructing
current and future therapeutics were presented. Rolf Mu ̈ller
(Helmholtz Institute for Pharmaceutical Research Saarland,
Germany) talked about two great discoveries in natural
product science, cystobactamids, which are highly potent
novel antibacterial compounds,55 and griselimycin derivatives,
which are active against M. tuberculosis.56 Michael P. Manns
(Hannover Medical School, Germany) talked about how his
team has been ﬁghting hepatitis C by developing various forms
of therapy, many of which have become standard care for
hepatitis C worldwide.57−60 These exciting talks were followed
by those from Lixin Zhang (Institute of Microbiology,
China),61,62 Rainer Haag (Freie Universitaẗ Berlin, Ger-
many),63,64 and Mariá Maneiro (Concepción Gonzaĺez-Bello
group, Universidad e Santiago de Compostela, Spain),65 who
came up with novel ways and natural product compounds to
ﬁght various infectious diseases. Clearly, extensive background
knowledge in this ﬁeld is key to generating novel therapeutics
in the continuing ﬁght against infectious diseases.
■ CHEMINFORMATICS AND CHEMICAL SYSTEMS
BIOLOGY
The next session was “Cheminformatics and Chemical Systems
Biology,” which included the special topic “Quality of Chemical
Probes.” The use of chemicals to control or monitor cellular
phenotype has much in common with small-molecular
therapeutics to control disease-related biomolecules (Figure
1).66 The past decade of eﬀort by academic researchers has
advanced chemical biology, since it is a powerful way to ﬁll the
gap between the vast numbers of new genes that have been
discovered and the lack of validated drug targets and ways to
modulate them. The eﬀorts have borne fruit, resulting in novel
technologies, novel chemical tools to study cellular functions,
and novel lead compounds for medicines, but the development
of useful reagents with high potency, high selectivity, and a
proven mechanism of action remains challenging. Indeed, some
commercially available drugs, or historically established
chemical probes, are nonselective when used in complex
biological systems.67 Under the circumstances, the important
question is, how can we establish the selectivity of chemical
probes and better evaluate the biological phenomena reported
by their actions?
The ﬁrst speaker in the session, Jordi Mestres (Institut
Hospital del Mar d’Investigacions Me ̀diques, Spain),
discussed how the eﬀect of polypharmacology can be studied
by computational approaches.68 Polypharmacology, i.e., mod-
ulation of multiple targets at the same time by a single drug, is
currently considered a unique advantage of small-molecule-
based medicine over other modes of therapy.69,70 The
important question is, how can one evaluate the eﬀect of
polypharmacology correctly in order to predict the therapeutic
eﬃcacy? The speaker talked about the power of advanced bio-
and chemo-informatics for this purpose. Tudor Oprea
(University of New Mexico School of Medicine, USA)
clearly described the status of current drug and protein
discovery based on data acquired from over 100 omics and
informatics sources, eﬀort funded through a Common Funds
initiative (NIH U54 CA189205). Using metrics derived from
text mining, patent analytics, antibodies, and other sources, he
categorized ∼38% of the human proteome (7681 proteins) as
“Tdark,” i.e., functionally enigmatic proteins or the so-called
“ignorome.”71 Another 592 proteins (2.9%) have a conﬁrmed
Figure 1. Similarities and diﬀerences between pharmaceutical research and chemical biology.
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mechanism of action for approved drugs (“Tclin”). Two other
categories reﬂect levels of literature, functional and disease
annotations (“Tbio,” 53.1%) and knowledge about (potent)
small molecules (“Tchem,” 5.9%). He noted that there appears
to be a knowledge deﬁcit, i.e., we lack understanding of protein
function for 38% of the human proteome, and that less than 3%
of the human proteome is therapeutically addressed by drugs.
Given our current understanding of disease concepts, he
estimated that more than 70% of human diseases are currently
unaddressed by a therapeutic agent. Thus, the ﬁeld of drug
discovery is wide open. Better chemical tool compounds are
one of the key pathways to construct good drugs.5
Besides specialized informatics studies, the enrichment of
public databases accessible to drug discovery scientists is an
important way to facilitate the connection between chemical
biology and drug discovery, and a study based on three public
databases was introduced. ChEMBL72 (https://www.ebi.ac.uk/
chembl/) is an established database for chemical biology, along
with PubChem, and Prudence Mutowo (EMBL, Germany)
showed how the combination of the ChEMBL database and a
gene ontology platform is valuable for navigating the target
space of speciﬁed proteins, to understand which chemicals
target a protein of interest, and to glean the biology inﬂuenced
by the chemicals. Albert A. Antolin (Institute of Cancer
Research, UK) pointed out the diﬃculty in target validation of
tool compounds in cancer translational research. He demon-
strated how the precise scoring of chemobiological data and its
interpretation can be facilitated with the canSAR (https://
cansar.icr.ac.uk/) database platform, assisting the study of
deregulated proteins in cancer cells.73,74 In the last session,
Jonathan Baell (Monash University, Australia) introduced
the relatively new public database, Chemical Probes Portal
(http://www.chemicalprobes.org/), which was designed to
address the above-mentioned problems of quality evaluation
of chemical probes, which frequently gives rise to questionable
compounds he has coined pan-assay interference compounds
(PAINS).66 In the database, researchers can access information
such as the best available chemical probe for a protein of
interest, along with the latest information on activity and
selectivity, and suitable control compounds for biological
studies. If the evaluation is done correctly and the probes are
used properly, studies of various biological events could
become more robust and reliable, so this database has the
potential to aid the generation of valuable pharmaceutical
drugs. This again stresses the importance of expanding this ﬁeld
and promoting worldwide communications and granting access
to research data.
■ MOLECULAR IMAGING
The next session was “Molecular Imaging.” Carsten Schultz
(EMBL, Germany) introduced his latest discoveries concern-
ing the development of tools to manipulate cellular function.
Manipulation and visualization of cellular events are two
important aspects in technology development, and his talk
summarized how chemical knowledge can contribute to
developing technologies in both areas, and how their
combination can generate novel biological discoveries. As an
example, he introduced his latest research results on under-
standing how lipid signaling, e.g., by diacylglycerol, is
spatiotemporally mediated.75,76 Development of another
synthetic biological tool was discussed by Toru Komatsu
(The University of Tokyo, Japan),77,78 and work on tools for
bioimaging was presented by Vankata Pavan Kumar Kondapi
(University of Alberta, Canada), who described an eﬀort to
develop a smart tool to visualize GLUT5 activity using a
GLUT5-selective sugar moiety,79 and Orsolya Demeter
(Hungarian Academy of Sciences, Hungary), who developed
a ﬂexible platform for multivalent ﬂuorogenic labels80 via
double-click techniques. As is popularly said, “seeing is
believing,” and ﬂuorescence imaging is one of the ways that
researchers can get valuable information on intracellular events
by direct observation. Molecular imaging is being used more
and more in drug discovery and development,81 as well as
disease diagnosis,82 so we can expect a lot more progress in the
ﬁeld in the near future.
■ PROBING THE STRUCTURE AND FUNCTION OF
PTMS
The next session was dedicated to post-translational
modiﬁcations (PTMs). When studying substrates bearing
PTMs, a common challenge arises from complications
associated with the preparation of site-speciﬁcally modiﬁed
substrates bearing a well-deﬁned PTM. Another challenge is
associated with the detection and enrichment of substrates
modiﬁed with distinct PTMs. Chemical biology approaches
have greatly advanced this area, and it was ﬁtting that a session
was dedicated to this topic.
The session was kicked oﬀ by Hilal Lashuel (Ecole
Polytechnique Federale de Lausanne, Switzerland). Hilal
reported the total chemical synthesis of post-translationally
modiﬁed forms of α-synuclein (α-syn). Parkinson’s disease is
associated with neuronal protein aggregates (Lewy bodies)
which contain high concentrations of post-translationally
modiﬁed α-syn. The identiﬁcation of a PTM that is associated
with pathogenicity will be an important discovery and could
serve as a novel therapeutic target for Parkinson’s disease. Hilal
described the synthesis and characterization of an array of
modiﬁed forms of α-syn.83−87 The next speaker was Carlo
Unverzagt (University of Bayreuth, Germany). Carlo
described work from his lab involving the convergent synthesis
of homogeneous glycoforms of human interleukin-6.88 Protein
semisynthesis can present a number of technical challenges, and
Carlo described a raft of chemical ligation strategies that were
necessary for successful synthesis.89 Dorothea Fiedler
(Leibniz-Institut fu ̈r Molekulare Pharmakologie, Germany)
next spoke on her studies of the arcane PTM pyrophosphor-
ylation. Dorothea’s talk described the development of the tools
necessary to study this poorly characterized PTM. These
included nonhydrolyzable analogues,90 production of pyro-
phosphopeptides,91 and metal complexes for enrichment and
detection.92,93 The tools reported should be invaluable for
studying pyrophosphorylation and establishing its cellular role.
The next speaker was Yao-Wen Wu (Chemical Genomics
Centre of the Max Planck Society, Germany). Regulation of
autophagosome formation is mediated by modiﬁcation of the
phosphatidylethanolamine headgroup, displayed on autopha-
gosome membranes, with the ubiquitin-like protein, LC3.
Removal of LC3 can be carried out by the Legionella eﬀector
protein RavZ, yet the mechanism is poorly understood. The
talk described the semisynthesis of lipidated forms of LC3
which provided novel insight into how pathogenic eﬀectors
subvert the host’s autophagy machinery.94 Satpal Virdee
(MRC Protein Phosphorylation and Ubiquitylation Unit,
UK) spoke next and described the design and development of
novel activity-based probes (ABPs) that proﬁle the trans-
thiolation activity associated with E1 activating enzymes95 and
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ubiquitin E3 ligating enzymes.96 In proof-of-concept work, he
reported the proﬁling of the Parkinson’s disease-associated E3
ligase Parkin, revealing a number of insights into the pathology
and mechanism of this enzyme.96
The ﬁnal talk was a Keynote Lecture from Jason Chin
(MRC Laboratory of Molecular Biology, UK). Jason
discussed a large body of work from his lab using genetic
code expansion approaches to interrogate PTMs and protein
function in general. Genetic methods for directing the
incorporation of PTMs are a powerful complement to chemical
methods. In principle, genetic methods can be used to prepare
site-speciﬁcally modiﬁed substrate proteins in the native state
(i.e., no requirement for substrate assembly from constituent
peptide building blocks followed by protein folding). In
principle, this makes large substrates and those not amenable
to artiﬁcial folding accessible. A number of strategies were
described for genetically incorporating, or directing, a number
of PTMs including acetylation,97 ubiquitination,98,99 and
phosphorylation.100 Approaches for acetylation and ubiquitina-
tion were used to provide novel biological insights into
chromatin dynamics97 and deubiquitinating enzyme speciﬁc-
ity,98 respectively. Jason also spoke about an exciting new
technology dubbed genetically directed bioorthogonal ligand
tethering (BOLT) for the selective and reversible regulation of
protein activity in cells.101 This provides an alternative but
conceptually similar strategy to the “bump and hole” methods
described earlier.43,45
An important part of the conference was the excellent poster
sessions that were accompanied by short “speed” talks. Prizes
were awarded, kindly provided by WileyChembiochem and
Sanoﬁ, to those considered the best. The recipients were
Benjami ́Oller-Salvia (IRB Barcelona), Dominik Schumacher
and Florian A. Mann (Leibniz-Institut für Molekulare
Pharmakologie, Germany), Jan-Philip Schuelke (Pﬁzer,
Boston), Elles Ostensen (University of Oslo, Norway),
Abukakar Jalloh (Albert Einstein College, USA), and Anuchit
Phanumartwiwath (Oxford University, UK).
The ICBS and ECBS are young organizations that were
launched less than 10 years ago. The joint meeting held in
Berlin was a testament to the momentum the societies have
attained. The quality and diversity of science was a true
reﬂection of the very best in international chemical biology and
we look forward to what the 2016 meeting will bring, to be held
in Madison, Wisconsin.
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